Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-08-08 | Reverse | 1:200 |
| 2024-04-16 | Reverse | 1:25 |
NuCana plc is a UK-based clinical-stage biopharma developing cancer treatments using its proprietary ProTide technology, with lead candidates like Acelarin and NUC-3373 in various clinical trial phases.

A clinical-stage anti-cancer agent developed using NuCana's proprietary ProTide technology. It is currently in a Phase 1/2 study for advanced solid tumors and melanoma, representing the company's most prominent and actively advancing drug candidate.
Overall rating: B
| PEER | PRICE | |
|---|---|---|
PTHS | $24.73 | COMPARE |
ENLV | $1.35 | COMPARE |
LSTA | $1.69 | COMPARE |
NRSN | $0.42 | COMPARE |
PASG | $4.52 | COMPARE |
GDTC | $0.92 | COMPARE |
CLGN | $0.36 | COMPARE |
MTVA | $1.70 | COMPARE |